Bruce Montgomery

Active 1995–2025

98
Papers
22,701
Citations
59
h-index
89
i10-index

Citations

Citations per year for Bruce Montgomery1996: 2 citations1997: 7 citations1998: 14 citations1999: 10 citations2000: 11 citations2001: 24 citations2002: 19 citations2003: 30 citations2004: 26 citations2005: 10 citations2006: 15 citations2007: 22 citations2008: 34 citations2009: 76 citations2010: 89 citations2011: 109 citations2012: 95 citations2013: 141 citations2014: 112 citations2015: 149 citations2016: 238 citations2017: 288 citations2018: 383 citations2019: 1,003 citations2020: 1,208 citations2021: 1,291 citations2022: 980 citations2023: 641 citations2024: 1,089 citations2025: 498 citations2026: 13 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,048 citing papers, 30.4% of this breakdownChina: 950 citing papers, 9.5% of this breakdownUnited Kingdom: 679 citing papers, 6.8% of this breakdownCanada: 540 citing papers, 5.4% of this breakdownItaly: 442 citing papers, 4.4% of this breakdownGermany: 412 citing papers, 4.1% of this breakdownAustralia: 326 citing papers, 3.3% of this breakdownSpain: 315 citing papers, 3.1% of this breakdownFrance: 298 citing papers, 3% of this breakdownJapan: 247 citing papers, 2.5% of this breakdownNetherlands: 244 citing papers, 2.4% of this breakdownSwitzerland: 209 citing papers, 2.1% of this breakdown
0%30.4%Other 23%

Fields

  • Medicine67.2%
  • Biochemistry, Genetics and Molecular Biology26.3%
  • Computer Science2.1%
  • Immunology and Microbiology1.6%
  • Engineering1%
  • Neuroscience0.3%
  • Other1.5%

Topics

  • Prostate Cancer Treatment and Research15.9%
  • Prostate Cancer Diagnosis and Treatment6%
  • Cancer Genomics and Diagnostics5.1%
  • Cancer Cells and Metastasis3.8%
  • Cancer, Lipids, and Metabolism3.1%
  • PARP inhibition in cancer therapy2.5%
  • Other63.6%

Coauthors

All papers

Open in search
  1. Integrative Clinical Genomics of Advanced Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Victor E. Reuter, Anuradha Gopalan, Jianjiong Gao, Massimo Loda, Rosina T. Lis, Michaela Bowden, Stephen Balk, Glenn C. Gaviola, Carrie Sougnez, Manaswi Gupta, Evan Y. Yu, Elahe A. Mostaghel, Heather H. Cheng, Hyojeong Mulcahy, Lawrence D. True, Stephen R. Plymate, Heidi Dvinge, Roberta Ferraldeschi, Penny Flohr, Susana Miranda, Zafeiris Zafeiriou, Nina Tunariu, Joaquı́n Mateo, Raquel Pérez-López, Francesca Demichelis, Brian D. Robinson, Marc Schiffman, David M. Nanus, Scott T. Tagawa, Alexandros Sigaras, Kenneth Eng, Olivier Elemento, Andrea Sboner, Elisabeth I. Heath, Howard I. Scher, Kenneth J. Pienta, Philip W. Kantoff, Johann S. de Bono, Mark A. Rubin, Peter S. Nelson, Levi A. Garraway, Charles L. Sawyers, Arul M. Chinnaiyan - Cell 2015 cited by 3,701

  2. Genomic correlates of clinical outcome in advanced prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bruce Montgomery, Himisha Beltran, Elisabeth I. Heath, Howard I. Scher, Philip W. Kantoff, Mary‐Ellen Taplin, Nikolaus Schultz, Johann S. de Bono, Francesca Demichelis, Peter S. Nelson, Mark A. Rubin, Arul M. Chinnaiyan, Charles L. Sawyers - National Academy of Sciences, Proceedings of the National Academy of Sciences 2019 cited by 1,408

  3. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Liying Zhang, Ahmet Zehir, Joseph Vijai, Howard I. Scher, Charles L. Sawyers, Nikolaus Schultz, Philip W. Kantoff, David B. Solit, Mark E. Robson, Eliezer M. Van Allen, Kenneth Offit, Johann S. de Bono, Peter S. Nelson - New England Journal of Medicine 2016 cited by 1,663

  4. The long tail of oncogenic drivers in prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wassim Abida, Barry S. Taylor, Howard I. Scher, Peter S. Nelson, Johann S. de Bono, Mark A. Rubin, Charles L. Sawyers, Arul M. Chinnaiyan, Nikolaus Schultz, Eliezer M. Van Allen - Nature Genetics 2018 cited by 884

  5. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2019 cited by 468

  6. Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

    Authors: , , , , , , , , , - Clinical Cancer Research 2008 cited by 2,183

  7. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , - Cell 2018 cited by 609

  8. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress

    Authors: , , , , , , , , , , , , , , , , - Cell Reports 2020 cited by 301

  9. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2016 cited by 763

  10. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion

    Authors: , , , - Nature Clinical Practice Urology 2009 cited by 889

  11. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2018 cited by 275

  12. Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference

    Authors: , , , , , , , , , , , - JAMA Oncology 2020 cited by 158

  13. Integrative Clinical Genomics of Advanced Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Victor E. Reuter, Anuradha Gopalan, Jianjiong Gao, Massimo Loda, Rosina T. Lis, Michaela Bowden, Stephen Balk, Glenn C. Gaviola, Carrie Sougnez, Manaswi Gupta, Evan Y. Yu, Elahe A. Mostaghel, Heather H. Cheng, Hyojeong Mulcahy, Lawrence D. True, Stephen R. Plymate, Heidi Dvinge, Roberta Ferraldeschi, Penny Flohr, Susana Miranda, Zafeiris Zafeiriou, Nina Tunariu, Joaquı́n Mateo, Raquel Pérez-López, Francesca Demichelis, Brian D. Robinson, Andrea Sboner, Marc Schiffman, David M. Nanus, Scott T. Tagawa, Alexandros Sigaras, Kenneth Eng, Olivier Elemento, Andrea Sboner, Elisabeth I. Heath, Howard I. Scher, Kenneth J. Pienta, Philip W. Kantoff, Johann S. de Bono, Mark A. Rubin, Peter S. Nelson, Levi A. Garraway, Charles L. Sawyers, Arul M. Chinnaiyan - Cell 2015 cited by 591

  14. Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth

    Authors: , , , , , , , - Cancer Research 2008 cited by 1,412

  15. The Androgen-Regulated Protease TMPRSS2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis

    Authors: , , , , , , , , , , , , , , , , , - Cancer Discovery 2014 cited by 493

  16. Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Steven Henikoff, Peter S. Nelson, Gavin Ha - Cancer Discovery 2022 cited by 68

  17. A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer

    Authors: , , , , , , , , , , , - PLoS ONE 2018 cited by 137

  18. Accelerating precision medicine in metastatic prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Cancer 2020 cited by 77

  19. Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2023 cited by 59

  20. CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade

    Authors: , , , , , , , , , , , , , , , , - JCO Precision Oncology 2020 cited by 90

  21. Inherited TP53 Variants and Risk of Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Piper Nicolosi, Robert L. Nussbaum, Lauren E. Schwartz, Zsofia K. Stadler, Judy E. Garber, Kenneth Offit, Joshua D. Schiffman, Peter S. Nelson, Oliver Sartor, Michael F. Walsh, Colin C. Pritchard - European Urology 2021 cited by 90

  22. Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA

    Authors: , , , , , , , , , - JAMA Oncology 2021 cited by 76

  23. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer

    Authors: , , , , , , , , , , , , - European Urology 2019 cited by 117

  24. Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies

    Authors: , , , , , , , , - PLoS ONE 2020 cited by 111